GOGOX (02246): Proposed Adoption of the 2026 Restricted Share Unit Scheme
GOGOX (02246) announced that the Board has resolved to propose the adoption of the 2026 Restricted Share Unit Scheme, which, if and when adopted, will constitute a share scheme funded by the issue of new shares under Chapter 17 of the Listing Rules. Accordingly, under the Listing Rules, the adoption of the 2026 Restricted Share Unit Scheme is subject to (i) approval by the Shareholders at the general meeting; and (ii) the Stock Exchange Listing Committee granting approval for the listing of, and permission to deal in, the shares which may be issued pursuant to the awards granted under the 2026 Restricted Share Unit Scheme.
GOGOX (02246) announced that the Board has resolved to propose the adoption of the 2026 Restricted Share Unit Scheme, which, if and when adopted, will constitute a share scheme funded by the issue of new shares under Chapter 17 of the Listing Rules. Accordingly, under the Listing Rules, the adoption of the 2026 Restricted Share Unit Scheme is subject to (i) approval by the Shareholders at the general meeting; and (ii) the Stock Exchange Listing Committee granting approval for the listing of, and permission to deal in, the shares which may be issued pursuant to the awards granted under the 2026 Restricted Share Unit Scheme.
Related Articles
Far exceeds expectations! Super Micro Computer, Inc. (SMCI.US) quarterly revenue approaches $19.5 billion, Wall Street hails it as a "clear positive signal"
MINSHENG EDU (01569) has been granted a revolving loan of up to RMB 300 million.
Shanghai Yizhong Pharmaceutical (688091.SH): First dosing of the first dose cohort completed in Phase I clinical trial of innovative drug YXC-001
Far exceeds expectations! Super Micro Computer, Inc. (SMCI.US) quarterly revenue approaches $19.5 billion, Wall Street hails it as a "clear positive signal"
MINSHENG EDU (01569) has been granted a revolving loan of up to RMB 300 million.
Shanghai Yizhong Pharmaceutical (688091.SH): First dosing of the first dose cohort completed in Phase I clinical trial of innovative drug YXC-001
